# Metastatic Colorectal Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-colorectal-cancer

> 10 upcoming FDA catalysts in metastatic Colorectal Cancer: volrustomig (AZN) on Jun to Sep 2027 (topline data readout); volrustomig (AZN) on June 2027 (primary completion); telisotuzumab adizutecan (ABBV) on August 2027 (primary completion); telisotuzumab adizutecan (ABBV) on Aug to Nov 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 19, 2026 | [Encorafenib primary completion](https://sec-api.dev/pdufa/encorafenib) | PFE | Metastatic Colorectal Cancer | completed | "NCT05217446 (A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05217446)) |
| Jun to Sep 2027 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Colorectal Cancer | scheduled | "NCT06792695 (A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06792695)) |
| June 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Colorectal Cancer | scheduled | "NCT06792695 (A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06792695)) |
| August 2027 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06614192 (A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614192)) |
| Aug to Nov 2027 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06614192 (A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614192)) |
| September 2027 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Colorectal Cancer | scheduled | "NCT05608044 (A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608044)) |
| Sep to Dec 2027 | [Botvymo® (botensilimab) topline data readout](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Colorectal Cancer | scheduled | "NCT05608044 (A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608044)) |
| March 2028 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06820463 (A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820463)) |
| Mar to Jun 2028 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06820463 (A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820463)) |
| Sep to Dec 2028 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Metastatic Colorectal Cancer | scheduled | "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252649)) |
| September 2028 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Metastatic Colorectal Cancer | scheduled | "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252649)) |

## Drugs

- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-colorectal-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Colorectal Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-colorectal-cancer

```bibtex
@misc{secapidev_indications_metastatic_colorectal_cancer_20261116,
  title        = {Metastatic Colorectal Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-colorectal-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_colorectal_cancer_20261116","title":"Metastatic Colorectal Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-colorectal-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
